Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

被引：56

作者：

Aigner, Maria ^{[1
]}

Lass-Floerl, Cornelia ^{[1
]}

机构：

[1] Med Univ Innsbruck, Inst Hyg & Med Microbiol, Schopfstr 41, A-6020 Innsbruck, Austria

来源：

JOURNAL OF FUNGI | 2020年 / 6卷 / 02期

关键词：

amphotericin B; oral availability; antifungals; cochleates; MAT2203; DRUG-DELIVERY; EFFICACY; ANTIFUNGAL; COCHLEATE; MODEL;

D O I：

10.3390/jof6020066

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds. However, the main drawback of the present formulations remains its toxicity, the limited use to intravenous administration, and the higher costs associated with the better tolerated lipid formulations. The novel nanoparticle-based encochleated AmB (CAmB) formulation encapsulates, protects, and delivers its cargo molecule AmB in the interior of a calcium-phospholipid anhydrous crystal. Protecting AmB from harsh environmental conditions and gastrointestinal degradation, CAmB offers oral availability in conjunction with reduced toxicity. Matinas BioPharma, Bedminster, NJ is on the way to develop CAmB named MAT2203, currently undergoing Phase II clinical trials.

引用

页数：7

共 31 条

[1] Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii [J].

Batista-Duharte, A. ;

Lastre, M. ;

Romeu, B. ;

Portuondo, D. L. ;

Tellez-Martinez, D. ;

Manente, F. A. ;

Perez, O. ;

Carlos, I. Z. .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 40 :277-287

[2]

Bhosale R.R., 2013, J. Sci. Ind. Res., V2, P964

[3]

Biederdorf F., 2009, ORAL ADM AMPHOTERICI

[4] Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis [J].

Delmas, G ;

Park, S ;

Chen, ZW ;

Tan, F ;

Kashiwazaki, R ;

Zarif, L ;

Perlin, DS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2704-2707

[5]

European Patent Office, 2014, European Patent, Patent No. [12177817.9, 12177817]

[6] Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy [J].

Faustino, Celia ;

Pinheiro, Lidia .

PHARMACEUTICS, 2020, 12 (01)

[7] Alteration in cellular viability, pro-inflammatory cytokines and nitric oxide production in nephrotoxicity generation by Amphotericin B: involvement of PKA pathway signaling [J].

Franca, F. D. ;

Ferreira, A. F. ;

Lara, R. C. ;

Rossoni, J. V., Jr. ;

Costa, D. C. ;

Moraes, K. C. M. ;

Tagliati, C. A. ;

Chaves, M. M. .

JOURNAL OF APPLIED TOXICOLOGY, 2014, 34 (12) :1285-1292

[8]

Gibson Brian, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P873

[9] Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity [J].

Hamill, Richard J. .

DRUGS, 2013, 73 (09) :919-934

[10]

Kalbag S, 2009, ORAL ADM AMPHOTERICI

← 1 2 3 4 →